Search Medical Condition
Please enter condition
Please choose location

Trelaze, France Clinical Trials

A listing of Trelaze, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (278) clinical trials

Tysabri Observational Program

TOP is an epidemiological observational study of participants receiving natalizumab, with each participant to be followed for up to 10 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use, and the impact of treatment ...

Phase N/A

0.0 miles

Learn More »

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two protocol numbers: 1160.129 for non-EU (European Union) ...

Phase N/A

0.0 miles

Learn More »

Frequency of Pompe's Disease and Neuromuscular Etiologies in Patients With Restrictive Respiratory Failure Associated With Signs of Muscle Weakness

A breach of respiratory function may be one of the elements more or less early or predominant clinical picture of neuromuscular diseases. It is considered that the obstructive syndromes represent 64% and restrictive or mixed syndromes 36% of chronic respiratory insufficiency, approximately 7% due to a neuromuscular disease. The frequency ...

Phase N/A

0.0 miles

Learn More »

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer

OBJECTIVES: Primary - To determine the objective tumor response rate in patients with locally advanced or metastatic papillary renal cell carcinoma treated with sunitinib malate. Secondary - To evaluate the safety of this drug in these patients. - To determine time-to-event variables of overall survival, time to disease progression, time ...

Phase

3.61 miles

Learn More »

Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants

In renally impaired patients with acute venous thromboembolism (VTE), standard-of-care (SOC) anticoagulation, i.e. heparins-vitamin K antagonists (VKA), at therapeutic dosage is associated with an increased risk of thromboembolic and bleeding complications compared to patients with normal renal function. These patients represent more than 20% of the VTE population in clinical ...

Phase

3.82 miles

Learn More »

Coupling Repetitive Transcranial Magnetic Stimulation With a Neuronavigation System in Treatment Resistant Depression

Background : Repetitive Transcranial Magnetic Stimulation (rTMS) is a new tool for major depressive disorder. rTMS is a non invasive technique allowing for a localized stimulation of cerebral tissue cortex. rTMS uses electromagnetic induction to induce weak electric currents using a rapidly changing magnetic field; this can modify activity in ...

Phase

4.04 miles

Learn More »

Restoration of the Radial Length in Compound Wrist Fractures Using Anterior Locking Plates

The fractures of the wrist, affecting the distal end of the radius are frequent, in particular in the old subject and/or osteoporotic. Beside the simple fractures treated by mini-invasive surgical methods, there is a considerable number of strong comminuted fractures for which no method of osteosynthesis proves completely satisfactory, especially ...

Phase N/A

4.34 miles

Learn More »

International Collaborative Gaucher Group (ICGG) Gaucher Registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The ...

Phase N/A

4.34 miles

Learn More »

Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)

Determined treatment efficacy and tolerability of second-line treatment in patients with small cell lung cancer comparing oral combinaison chemotherapy with intravenous combination chemotherapy.

Phase

4.34 miles

Learn More »

Lenalidomide in Subjects With intermediate2 or High MDS Associated With a Deletion (DEL) 5q [31]

Subjects meeting all inclusion and exclusion criteria will receive lenalidomide lenalidomide will be administered at 10 mg (two 5 mg capsules) once daily on Days 1–21, every 4 weeks. Bone marrow aspirate (baseline and during the course of the study at week 8, 16, 32, 52 and when clinically indicated/for ...

Phase

4.34 miles

Learn More »